<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>News – Bendalis</title>
	<atom:link href="https://bendalis.com/en/aktuelles/feed/" rel="self" type="application/rss+xml" />
	<link>https://bendalis.com/en</link>
	<description>Your specialist for sterile products in the hospital sector</description>
	<lastBuildDate>Thu, 30 Apr 2026 14:19:19 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updateperiod>
	per hour	</sy:updateperiod>
	<sy:updatefrequency>
	1	</sy:updatefrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bendalis.com/site/wp-content/uploads/logo.svg</url>
	<title>News – Bendalis</title>
	<link>https://bendalis.com/en</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Vancomycin available again – Bendalis ensures supply</title>
		<link>https://bendalis.com/en/vancomycin-available-again-bendalis-ensures-supply/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Sun, 01 Mar 2026 15:34:40 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">http://draft.bendalis.com/?p=3034</guid>

					<description><![CDATA[We are pleased to inform our customers and partners that Vancomycin Bendalis is once again available in both strengths (500 mg and 1000 mg). Packs of 10 of both variants will be ready for dispatch from 1 March 2026. The renewed availability is the result of intensive work on new production capacities: Bendalis has successfully integrated an additional manufacturing facility in Spain into the […]]]></description>
		
		
		
			</item>
		<item>
		<title>5FU available again – secure supply through Bendalis</title>
		<link>https://bendalis.com/en/5-fu-is-available-again-ensuring-a-secure-supply-through-bendalis/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Sunday, 1 March 2026 15:33:00 GMT</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">http://draft.bendalis.com/?p=3032</guid>

					<description><![CDATA[We are pleased to inform our customers and partners that 5Fluorouracil (5FU) is available again with immediate effect. Through our consistent work on a stable, resilient supply chain and close coordination with the responsible authorities, the supply situation has been successfully secured. The recently granted approval of the corresponding variation by the BfArM confirms the quality and reliability of our […]]]></description>
		
		
		
			</item>
		<item>
		<title>Stronger together: Bendalis to take over Sugammadex along with worldwide distribution rights</title>
		<link>https://bendalis.com/en/together-stronger-bendalis-acquires-sugammadex-with-worldwide-distribution-rights/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Wed, 01 Jan 2025 15:32:00 GMT</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">http://draft.bendalis.com/?p=3030</guid>

					<description><![CDATA[As of 1 January 2025, Bendalis GmbH has acquired the product Sugammadex in its entirety, including all global distribution rights, from Biofactor GmbH. This step marks a significant expansion of our international activities and creates clear, reliable, and long-term prospects for our partners and customers. With the acquisition, all existing customer relationships, contractual rights, and all relevant distribution structures […]]]></description>
		
		
		
			</item>
		<item>
		<title>Somatostatin Lyomark 3 mg: Distribution Partnership with Inresa Arzneimittel</title>
		<link>https://bendalis.com/en/somatostatin-lyomark-3-mg_inresa_bendalis/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Fri, 08 Dec 2023 10:18:00 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Bendalis]]></category>
		<category><![CDATA[Bendalis GmbH]]></category>
		<category><![CDATA[Inresa]]></category>
		<category><![CDATA[Somatostatin]]></category>
		<category><![CDATA[Somatostatin 3mg]]></category>
		<category><![CDATA[Somatostatin acetat]]></category>
		<category><![CDATA[Somatostatin Lyomark 3mg]]></category>
		<guid ispermalink="false">https://bendalis.com/?p=2156</guid>

					<description><![CDATA[Oberhaching, December 2023 Bendalis GmbH and Inresa Arzneimittel GmbH today announce their new distribution partnership for Somatostatin Lyomark 3 mg. Through this partnership, Inresa will be the sales and distribution partner for the product. Inresa was chosen as a strategic distributor to continue meeting the demand for Somatostatin and ensure patient care. Furthermore, Inresa is […]]]></description>
		
		
		
			</item>
		<item>
		<title>Changes in Management at Bendalis GmbH and Lyomark Pharma GmbH</title>
		<link>https://bendalis.com/en/changes-in-management-at-bendalis-gmbh-and-lyomark-pharma-gmbh-2/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Mon, 11 Apr 2022 08:32:46 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">https://bendalis.com/?p=2072</guid>

					<description><![CDATA[Oberhaching, April 2022

Dear Sir or Madam,

Today, we are informing you about a change in personnel at Bendalis GmbH and Lyomark Pharma GmbH. Mr. Parvany will be leaving the companies on 31 March 2022. Mr. Parvany has been active in both companies since 2012, initially as Head of Sales and Marketing and since 2017 as Managing Director. […]]]></description>
		
		
		
			</item>
		<item>
		<title>Changes in Management at Bendalis GmbH and Lyomark Pharma GmbH</title>
		<link>https://bendalis.com/en/changes-in-management-at-bendalis-gmbh-and-lyomark-pharma-gmbh/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Tue, 21 Sep 2021 14:37:57 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">https://bendalis.com/?p=2045</guid>

					<description><![CDATA[Oberhaching, 21.09.2021

Dear Sir or Madam,

Today we wish to inform you about a change in personnel at Bendalis GmbH and Lyomark Pharma GmbH. Mr Malocho will be leaving the companies on 30.09.2021. Mr Malocho has been working at both companies since 2006, initially as Head of Supply Chain and since 2014 as Managing Director. We would like to thank you [...]]]></description>
		
		
		
			</item>
		<item>
		<title>Inceptua and Bendalis enter into an exclusive agreement for clinical trials of oncology drugs</title>
		<link>https://bendalis.com/en/inceptua-and-bendalis-sign-exclusive-contract-for-oncology-drugs/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Mon, 25 Nov 2019 14:00:48 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Bendalis GmbH]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Inceptua]]></category>
		<guid ispermalink="false">https://bendalis.com/?p=1940</guid>

					<description><![CDATA[BERLIN / MUNICH – 25 November 2019 – Inceptua Group (formerly Multipharma GmbH), a global pharmaceutical company and service partner, and Bendalis GmbH, a German manufacturer of generic oncology products and specialised therapeutics, today announced the signing of an exclusive agreement for the supply of clinical trial materials for generic oncology products. This agreement will make Inceptua the exclusive distribution partner for the products of […]]]></description>
		
		
		
			</item>
		<item>
		<title>Change in management</title>
		<link>https://bendalis.com/en/change-in-management/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Sat, 01 Jul 2017 10:15:19 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">https://bendalis.com/wechsel-in-der-geschaftsfuhrung/</guid>

					<description><![CDATA[Wechsel an der Spitze der Bendalis GmbH: Christian Parvany (39) wechselt ab 1. Juli in die Geschäftsführung des Unternehmens. Gleichzeitig beendet Dr. Helmut Wolf seine mehr als zehnjährige Tätigkeit als Geschäftsführer bei der Bendalis. Dr. Wolf bleibt dem Unternehmen als Gesellschafter erhalten und wird die Entwicklung unseres Unternehmens in dieser Funktion weiterbegleiten. Christian Parvany ist [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>New therapy: skin and mucous membrane care with cannabinoids</title>
		<link>https://bendalis.com/en/new-therapy-for-skin-and-mucous-membrane-care-with-cannabinoids/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Tue, 26 May 2015 10:26:33 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">https://bendalis.com/neue-therapie-haut-und-schleimhautpflege-mit-cannabinoiden/</guid>

					<description><![CDATA[Die Rolle der körpereigenen Cannabinoide bei Haut- und Schleimhautentzündungen Zu den häufigsten Nebenwirkungen einer Krebstherapie zählen Haut- und Schleimhautschäden. Diese beeinträchtigen die Lebensqualität der Patienten, aber auch den Erfolg der Therapie. Die Therapie bei Krebserkrankungen zielt darauf ab, das Wachstum des Tumors zu bremsen oder gar zu stoppen. Dabei wird die Fähigkeit der Zellen sich [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Cancer therapy is more bearable with Again-Life medical products</title>
		<link>https://bendalis.com/en/medical-products-make-cancer-therapy-more-bearable-again/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Tue, 26 May 2015 10:21:51 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">https://bendalis.com/mit-again-life-medizinprodukten-wird-krebstherapie-ertraglicher/</guid>

					<description><![CDATA[Haut- und Schleimhautschutz in der Krebstherapie – dies kennzeichnet die Again-Life-Medizinprodukte, wenn es gilt, Nebenwirkungen einer Chemo- oder Strahlentherapie zu minimieren oder gar zu verhindern. Der bewährte und patentierte Wirkstoff Adelmidrol ist das Außergewöhnliche an der Again-Life-Produktlinie, die jetzt von der Bendalis GmbH, Oberhaching, in die Apotheken eingeführt wurde. www.againlife.de Der von dem italienischen Internisten [&#8230;]]]></description>
		
		
		
			</item>
	</channel>
</rss>